The Intersection of Autoimmunity and Sleep: Anti-IgLON5 as the Key Player in a Case Series
Abstract
Anti-IgLON5 disease is a recently identified autoimmune condition characterized by unique sleep disturbances and a broad spectrum of neurological symptoms. Alongside prominent manifestations such as bulbar dysfunction, gait abnormalities, movement disorders, and cognitive decline, affected individuals often experience severe and characteristic sleep disorders. These include parasomnias during both rapid eye movement (REM) and non-REM (NREM) sleep, stridor, and obstructive sleep apnea (OSA). The presence of antibodies targeting IgLON5, a cell adhesion protein with a still unclear role, is a defining feature of the disease. Due to the limited number of reported cases and studies, anti-IgLON5 disease remains an important and emerging area of interest in sleep medicine research. This case series of seven patients highlights the importance of evaluating sleep-related symptoms not only in the context of sleep disorders but also through a comprehensive neurological history and examination. Such an approach is essential for identifying potential underlying conditions such as bulbar dysfunction, movement disorders, and cognitive impairment, which may indicate the rare autoimmune condition known as anti-IgLON5 disease.
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.